This article is about a drug. For other uses, see
Toralizumab ( IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders ( immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases ( multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/ small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease). [1 ]
In Phase II
clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted. [2 ]
The drug was developed by
IDEC Pharmaceuticals Corporation.
References [ edit ]
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
^ Luebke, Robert W; Robert V House; Ian Kimber (2007). . Target Organ Toxicology Series (3 ed.). Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 131. Immunotoxicology and immunopharmacology ISBN 0-8493-3790-9.